Related Experiment Video
Updated: Jun 16, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
11.7K
Integrin-deficient T cell leukemia accumulates in the central nervous system
Biorxiv : the Preprint Server for Biology
|March 23, 2026
Summary
Integrins VLA-4 and LFA-1 are not required for T-cell acute lymphoblastic leukemia (T-ALL) to enter the central nervous system (CNS). Integrin-deficient T-ALL actually proliferates more in the CNS, suggesting new combination therapy strategies.
Area of Science:
- Oncology
- Immunology
- Neuroscience
Background:
- T-cell acute lymphoblastic leukemia (T-ALL) frequently metastasizes to the central nervous system (CNS).
- Current CNS-directed chemotherapy for T-ALL can cause neurotoxicity and is often ineffective.
- The mechanisms of T-ALL CNS infiltration and persistence are poorly understood.
Purpose of the Study:
- To investigate the role of integrins VLA-4 and LFA-1 in T-ALL CNS entry and persistence.
- To explore potential therapeutic strategies targeting T-ALL CNS dissemination.
Main Methods:
- Utilized integrin-deficient T-ALL models to assess CNS entry and proliferation.
- Compared the CNS accumulation of integrin-deficient T-ALL versus control T-ALL.
- Evaluated the synergistic effects of integrin blockade and chemotherapy.
Main Results:
- VLA-4 and LFA-1 integrins were dispensable for T-ALL CNS entry.
- Integrin-deficient T-ALL exhibited increased proliferation within the CNS compared to controls.
- Integrin blockade showed synergy with chemotherapy targeting proliferating cells.
Conclusions:
- Integrin-mediated interactions may normally promote T-ALL quiescence in the CNS.
- Targeting integrins in combination with chemotherapy presents a promising therapeutic avenue for T-ALL CNS disease.
